

FOI 2980

31st March 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

MYELOPROLIFERATIVE DISEASES

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Fedratinib (Inrebic)	0
1.2 Momelotinib (Omjjara)	3
1.3 Ruxolitinib (Jakavi)	20
1.4 Hydroxycarbamide	168

Q2. How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Diagnosis with ICD10 codes	Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3	
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3	
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3	

2.4 Myeloproliferative Disease, Chronic
ICD10 code = D471, D47.1

--

Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
3.1 Ruxolitinib (Jakavi)	
3.2 Hydroxycarbamide	

Q4. How many patients with Polycythaemia Vera (ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
4.1 Ruxolitinib (Jakavi)	
4.2 Hydroxycarbamide	

NON-HODGKIN'S LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND ACUTE MYELOID LEUKAEMIA (AML)

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
5.1 Acalabrutinib (Calquence)	
5.2 Ibrutinib (Imbruvica)	
5.3 Pirtobrutinib (Jaypirca)	
5.4 Venetoclax (Venclyxto)	
5.5 Zanubrutinib (Brukinsa)	



5.6 Rituximab	
5.7 Obinutuzumab (Gazyvaro)	

Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
6.1 Acalabrutinib (Calquence)	
6.2 Ibrutinib (Imbruvica)	
6.3 Pirtobrutinib (Jaypirca)	
6.4 Venetoclax (Venclyxto)	
6.5 Zanubrutinib (Brukinsa)	
6.6 Obinutuzumab (Gazyvaro)	
6.7 Rituximab	
6.8 Bendamustine	
6.9 Chlorambucil	
6.10 Fludarabine	
6.11 Cyclophosphamide	

Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
7.1 Ibrutinib + venetoclax	
7.2 Obinutuzumab + venetoclax	

7.3 Zanubrutinib monotherapy / maintenance	
7.4 Ibrutinib monotherapy / maintenance	
7.5 Venetoclax monotherapy	
7.6 Venetoclax + rituximab	

Q8. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
8.1 Acalabrutinib	
8.2 Ibrutinib	
8.3 Zanubrutinib	

Q9. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
9.1 Azacitidine	
9.2 Cytarabine	
9.3 Venetoclax (Venclyxto)	

Q10. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available?

Name of combination	Number patients treated
10.1 Venetoclax + Azacitidine (<i>with or without posaconazole</i>)	
10.2 Venetoclax + Cytarabine (<i>inc. V + LDAC, V + ARAC, V+ ARA-C</i>)	



Southern Health and Social Care Trust

Response to Questions 2-10:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Email: Foi.Team@Southerntrust.hscni.net